Molina et al. Dupilumab (IL4/IL13 mab) in refractory EGPA. Complete response 49%, partial 43%. But flares in 27%. Dupilumab-induced eosinophilia in 57%. @RheumNow #ACR22 Abstr#1074
Safety and Efficacy of Dupilumab in Patients with Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis - ACR Meeting Abstracts
